Apr. 09 2024
Source Page: MHRA FOI performance dataFound: Valproate b) Carbamazepine c) Topiramate d) Levetiracetam e) Lamotrigine f) Pregabalin g) Phenytoin
Apr. 04 2024
Source Page: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use GuidelinesFound: Reproduction studies on sodium meclofenamate in comparison to aspirin and pheny lbutazone.
Asked by: Baillie, Jackie (Scottish Labour - Dumbarton)
Question
To ask the Scottish Government how many children have been affected as a consequence of their mothers being prescribed sodium valproate during pregnancy.
Answered by Minto, Jenni - Minister for Public Health and Women's Health
We do not know the numbers of children affected because the information has not been collected historically.
In response to the Independent Medicines and Medical Devices Safety Review (IMMDSR), the Scottish Government commissioned Public Health Scotland (PHS) to establish a medicines in pregnancy surveillance asset. This resource will support monitoring and reporting to progress improvements in the safe use of valproate and other teratogenic medicines in Scotland. Its first output is due to be published by PHS in April 2024 and will include prescribing data and trends for valproate and other anti-seizure medicines.
Mentions:
1: Baroness Cumberlege (Con - Life peer) valproate and pelvic mesh, published on 7 February. - Speech Link
2: Lord Markham (Con - Life peer) valproate and pelvic mesh. - Speech Link
3: Baroness Uddin (Non-affiliated - Life peer) On previous occasions, I have raised my ongoing concerns about the use of sodium valproate, especially - Speech Link
4: Baroness Bennett of Manor Castle (Green - Life peer) valproate and vaginal mesh victims. - Speech Link
Asked by: Baillie, Jackie (Scottish Labour - Dumbarton)
Question
To ask the Scottish Government what arrangements are in place to compensate any children that have been affected as a consequence of their mothers being given sodium valproate during pregnancy, and when it expects compensation payments to commence.
Answered by Minto, Jenni - Minister for Public Health and Women's Health
The Scottish Government will await the view and any decisions by the UK Government in relation to redress for anyone who was affected by exposure to valproate.
As set out in our letter to MSPs, this is because the recommendations on redress the UK Government is considering may involve a new agency and schemes that would be funded via a levy on manufacturers of medicines and medical devices and the Scottish Government has only limited powers under the devolution arrangements to impose levies.
We will of course update the Parliament about any important developments.
Asked by: Simon Jupp (Conservative - East Devon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the Hughes Report: Options for redress for those harmed by valproate and pelvic mesh, published by the Patient Safety Commissioner on 7 February 2024, whether she has made an assessment of the potential implication for her policies of the provision of financial redress for people harmed by valproate and pelvic mesh.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Government commissioned the Patient Safety Commissioner (PSC) to produce a report on redress for those affected by sodium valproate and pelvic mesh. We are grateful to the PSC and her team for completing this report and our sympathies remain with those affected by sodium valproate and pelvic mesh. The Government is now carefully considering the PSC’s recommendations and will respond substantively in due course.
Asked by: Cat Smith (Labour - Lancaster and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to The Hughes Report, published on 7 February 2024, if she will make an assessment of the potential merits of providing interim payments to victims of sodium valproate.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Government commissioned the Patient Safety Commissioner (PSC) to produce a report on redress for those affected by sodium valproate and pelvic mesh. We are grateful to the PSC and her team for completing this report and our sympathies remain with those affected by sodium valproate and pelvic mesh. The Government is now carefully considering the PSC’s recommendations and will respond substantively in due course.
Oral Evidence Mar. 19 2024
Inquiry: Proposals for backbench debatesFound: review, which was a review of all the historical evidence on Primodos, as well as on vaginal mesh and sodium
Asked by: Rosie Duffield (Labour - Canterbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what her planned timetable is for making a decision on redress for people affected by mesh implants following the publication of The Hughes Report on 7 February 2024.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Government commissioned the Patient Safety Commissioner (PSC) to produce a report on redress for those affected by sodium valproate and pelvic mesh. We are grateful to the PSC and her team for completing this report, and our sympathies remain with those affected by sodium valproate and pelvic mesh. The Government is now carefully considering the PSC’s recommendations, and will respond substantively in due course.